This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye ...
InvestorsHub on MSN
Tarsus to receive $15M milestone after China approves TP-03 eye therapy
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) said it will receive a $15 million milestone payment after China’s National Medical ...
The approval was obtained by Grand Pharmaceutical Group Limited (“Grand Pharma”), Tarsus’ exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis ...
Tarsus runs new 'Don’t Freak Out. Get Checked Out' eyelid disease campaign as FDA approval beckons
Tarsus is gearing up for a potential FDA green light of its experimental drug to treat a common but little-known eyelid inflammation disease and is wasting no time to boost awareness around the ...
How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin ...
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...
As part of its latest eye care campaign, Tarsus Pharmaceuticals has a simple message for patients with demodex blepharitis: Don’t Freak Out, Get Checked Out. Since May is Health Vision Month, the ...
IRVINE, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address patient needs, starting with eye care, through the application of proven ...
CEO Bobby Azamian highlighted that Tarsus Pharmaceuticals achieved over $78 million in XDEMVY sales during Q1 2025, reflecting a 217% year-over-year increase. Approximately 72,000 bottles were ...
Tarsus Pharmaceuticals is tackling a common eyelid condition that affects millions of Americans as part of its recently launched Look at the Lids campaign. The educational effort targets demodex ...
Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results